[Immunotherapy of tumors: from the first experimental studies to the recent clinical applications. I. Passive immunotherapy].
After a short introduction on the rationale of cancer Immunotherapy (IT), the Authors analyse the experimental and clinical treatments. Very interesting the results of the clinical trials with cells, used with success never reached before with the standards treatments. Particular emphasis has been dedicated to Lymphokine Activated Killers in association with Interleukin2 (IL2) and Tumor Infiltrating Lymphocytes, which have shown a very strong and specific anticancer activity. The encouraging therapeutical possibilities of the association with cytokines and immunosuppressors are also underlined. Monoclonal antibodies are considered a promising therapeutical approach which did'nt receive an effective clinical application, although their use as immunoconjugates with toxines chemotherapeutical and radioactive agents is giving incouraging results. Yet some technical and immunological problems remain to be solved for them to be used in the clinical setting against solid tumors.
Burrai
I
I
Università Cattolica del Sacro Cuore-Roma.
Di Lallo
A
A
D000906:Antibodies / Q000627:therapeutic use; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive / Q000379:methods*; D015979:Killer Cells, Lymphokine-Activated; D016246:Lymphocytes, Tumor-Infiltrating; D008264:Macrophages; D009369:Neoplasms / Q000628:therapy*
D000906:Antibodies; D007106:Immune Sera
Immunoterapia dei tumori: dai primi studi sperimentali alle recenti applicazioni cliniche. Parte I. Immunoterapia passiva.